Produção Nacional
Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review
2019; Baishideng Publishing Group; Volume: 25; Issue: 9 Linguagem: Inglês
10.3748/wjg.v25.i9.1142
ISSN2219-2840
AutoresAdérson Omar Mourão Cintra Damião, Matheus Freitas Cardoso de Azevedo, Alexandre de Sousa Carlos, Marcela Yumi Wada, Taciana Valéria Marcolino Silva, Flávio de Castro Feitosa,
Tópico(s)Pregnancy and Medication Impact
ResumoBACKGROUNDDespite the advent of biological drugs, conventional therapy continues to be used in moderate to severe inflammatory bowel disease (MS-IBD).This study hypothesized that as a standard of treatment and the primary alternative to biologics, conventional therapy should present robust effectiveness results in IBD outcomes. AIMTo investigate the effectiveness of conventional therapy for MS-IBD. METHODSA systematic review with no time limit was conducted in July 2017 through the Cochrane Collaboration, MEDLINE, and LILACS databases.The inclusion criteria encompassed meta-analyses, systematic reviews, randomized clinical trials, observational and case-control studies concerning conventional therapy in adult patients with MS-IBD, including Crohn's disease (CD) and ulcerative colitis (UC).Corticosteroids (prednisone, hydrocortisone, budesonide, prednisolone, dexamethasone), 5-aminosalicylic acid (5-ASA) derivatives (mesalazine and sulfasalazine) and immunosuppressants [azathioprine (AZA), methotrexate (MTX), mycophenolate, cyclosporine, tacrolimus, 6-mercaptopurine (6-MP)] were considered conventional therapy.The exclusion criteria were sample size below 50; narrative reviews; specific subpopulations (e.g., pregnant women, comorbidities); studies on postoperative IBD; and languages other than English, Spanish, French or Portuguese.The primary outcome measures were clinical remission (induction or maintenance), clinical response and mucosal healing.As
Referência(s)